Literature DB >> 22892876

Galectin-3 expression in prostate cancer and benign prostate tissues: correlation with biochemical recurrence.

Judith S Knapp1, Soum D Lokeshwar, Ulrich Vogel, Jörg Hennenlotter, Christian Schwentner, Mario W Kramer, Arnulf Stenzl, Axel S Merseburger.   

Abstract

BACKGROUND: Galactin-3 is a cell adhesion molecule involved in tumor progression. Our aim was to examine Gal-3 expression in tumor, benign tissue adjacent to the tumor (adjacent-benign) and benign prostate specimens and correlated it with biochemical recurrence.
MATERIALS AND METHODS: Tissue microarrays were prepared from 83 tumor, 78 adjacent-benign and 75 benign tissues obtained from 83 patients undergoing prostatectomy for clinically localized prostate cancer. Tissues were stained using a Gal-3 antibody and immunohistochemistry. The staining was graded between 0 and 300 depending upon staining intensity and the area of staining. In 37 patients on whom there was follow-up (Mean: 57.8 months; Median: 68 months), staining intensity was correlated with biochemical recurrence.
RESULTS: Gal-3 showed both nuclear and cytoplasmic localization in benign, adjacent-benign and tumor tissues. Median Gal-3 staining scores significantly decreased from benign (192.5) to adjacent-benign (148.8 p = 0.007) and to tumor (108.8; p < 0.0001) tissues. In univariate analysis, age (p = 0.028), Gleason sum (p = 0.007), T stage (p = 0.011), seminal vesicle invasion (p = 0.009), pre-operative prostate-specific antigen (p = 0.045) and Gal-3 staining in tumor tissues (0.018) significantly correlated with biochemical recurrence. In multivariate analysis, Gal-3 expression in tumor (p = 0.04), adjacent-benign (p = 0.037) and benign (p = 0.005) tissues significantly correlated with biochemical recurrence. Gal-3 staining in tumor tissues had 91.7 % sensitivity, 64 % specificity and 73 % accuracy in predicting biochemical recurrence.
CONCLUSIONS: This is the first study that showed a decreasing gradient of Gal-3 expression in benign, adjacent-benign and tumor tissues. Gal-3 expression may be useful in predicting biochemical recurrence.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22892876     DOI: 10.1007/s00345-012-0925-y

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  32 in total

1.  Clinical significance of Galectin-3 in clear cell renal cell carcinoma.

Authors:  Manabu Sakaki; Tomoharu Fukumori; Tomoya Fukawa; Essam Elsamman; Avirmed Shiirevnyamba; Hiroyoshi Nakatsuji; Hiro-omi Kanayama
Journal:  J Med Invest       Date:  2010-02

2.  EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.

Authors:  Axel Heidenreich; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Malcolm Mason; Vsevolod Matveev; Nicolas Mottet; Hans-Peter Schmid; Theo van der Kwast; Thomas Wiegel; Filliberto Zattoni
Journal:  Eur Urol       Date:  2010-10-28       Impact factor: 20.096

3.  Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression.

Authors:  F A van den Brûle; D Waltregny; F T Liu; V Castronovo
Journal:  Int J Cancer       Date:  2000-07-20       Impact factor: 7.396

4.  [Galectin expression in urological cancer. Diagnostic, prognostic and therapeutic potential].

Authors:  S Waalkes; A S Merseburger; A Simon; J Serth; M A Kuczyk
Journal:  Urologe A       Date:  2010-03       Impact factor: 0.639

5.  Tumor targeting and SPECT imaging properties of an (111)In-labeled galectin-3 binding peptide in prostate carcinoma.

Authors:  Susan L Deutscher; Said D Figueroa; Senthil R Kumar
Journal:  Nucl Med Biol       Date:  2009-02       Impact factor: 2.408

6.  Involvement of decreased Galectin-3 expression in the pathogenesis and progression of prostate cancer.

Authors:  Axel S Merseburger; Mario W Kramer; Jörg Hennenlotter; Perikles Simon; Judith Knapp; Jörg T Hartmann; Arnulf Stenzl; Jürgen Serth; Markus A Kuczyk
Journal:  Prostate       Date:  2008-01-01       Impact factor: 4.104

7.  Galectin-3, a beta-galactoside-binding animal lectin, is a marker of anaplastic large-cell lymphoma.

Authors:  K N Konstantinov; B A Robbins; F T Liu
Journal:  Am J Pathol       Date:  1996-01       Impact factor: 4.307

Review 8.  Secondary hormonal manipulation.

Authors:  Axel S Merseburger; Claus Belka; Klaus Behmenburg; Arnulf Stenzl
Journal:  Front Radiat Ther Oncol       Date:  2008

9.  The construction of high-density paraffin tissue microarrays with 0.43-mm-diameter paraffin tissue core biopsies is technically feasible.

Authors:  Ulrich F Vogel
Journal:  Virchows Arch       Date:  2008-06-13       Impact factor: 4.064

Review 10.  Molecular markers in prostate cancer: the role in preoperative staging.

Authors:  Judd W Moul; Axel S Merseburger; Shiv Srivastava
Journal:  Clin Prostate Cancer       Date:  2002-06
View more
  19 in total

1.  Galectin-3 knockdown increases gefitinib sensitivity to the inhibition of EGFR endocytosis in gefitinib-insensitive esophageal squamous cancer cells.

Authors:  Guanghui Cui; Mingwei Cui; Yuhang Li; Youguang Liang; Weihao Li; Haizhou Guo; Song Zhao
Journal:  Med Oncol       Date:  2015-03-19       Impact factor: 3.064

Review 2.  Galectins in cancer: carcinogenesis, diagnosis and therapy.

Authors:  Ali Hasan Ebrahim; Zainab Alalawi; Leonardo Mirandola; Rahman Rakhshanda; Scott Dahlbeck; Diane Nguyen; Marjorie Jenkins; Fabio Grizzi; Everardo Cobos; Jose A Figueroa; Maurizio Chiriva-Internati
Journal:  Ann Transl Med       Date:  2014-09

3.  Improving the detection of aggressive prostate cancer using immunohistochemical staining of protein marker panels.

Authors:  Qing Kay Li; Tung-Shing Mamie Lih; Yuefan Wang; Yingwei Hu; Naseruddin Höti; Daniel W Chan; Hui Zhang
Journal:  Am J Cancer Res       Date:  2022-03-15       Impact factor: 6.166

4.  Galactose specific lectins from prostate tissue with different pathologies: biochemical and cellular studies.

Authors:  Elene Davitashvili; George Burjanadze; Marine Koshoridze; Nana Koshoridze; Tamar Tsertsvadze; Nunu Mitskevich; Omar Tsintsadze; Guram Karazanashvili; Revaz Solomonia
Journal:  Mol Biol Rep       Date:  2021-11-05       Impact factor: 2.316

5.  Overexpression of the galectin-3 during tumor progression in prostate cancer and its clinical implications.

Authors:  Jiamin Gao; Tianyu Li; Zengnan Mo; Yanling Hu; Qiaoyong Yi; Rongquan He; Xiujuan Zhu; Xianguo Zhou; Shangyang She; Yingchun Chen
Journal:  Int J Clin Exp Pathol       Date:  2018-02-01

6.  The significance of galectin-3 as a new basal cell marker in prostate cancer.

Authors:  Y Wang; V Balan; X Gao; P G Reddy; D Kho; L Tait; A Raz
Journal:  Cell Death Dis       Date:  2013-08-01       Impact factor: 8.469

Review 7.  Galectins as new prognostic markers and potential therapeutic targets for advanced prostate cancers.

Authors:  Diego J Laderach; Lucas Gentilini; Felipe M Jaworski; Daniel Compagno
Journal:  Prostate Cancer       Date:  2013-09-24

8.  Effect of galectin-3 on the behavior of Eca‑109 human esophageal cancer cells.

Authors:  Ning Liang; Xiaoming Song; Jian Xie; Deguo Xu; Fengjun Liu; Xinshuang Yu; Yuan Tian; Zhen Liu; Lili Qiao; Jiandong Zhang
Journal:  Mol Med Rep       Date:  2014-11-05       Impact factor: 2.952

Review 9.  Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review).

Authors:  Rui Dong; Min Zhang; Qunying Hu; Shan Zheng; Andrew Soh; Yijie Zheng; Hui Yuan
Journal:  Int J Mol Med       Date:  2017-12-05       Impact factor: 4.101

10.  Prostate tumor DNA methylation is associated with cigarette smoking and adverse prostate cancer outcomes.

Authors:  Irene M Shui; Chao-Jen Wong; Shanshan Zhao; Suzanne Kolb; Ericka M Ebot; Milan S Geybels; Rohina Rubicz; Jonathan L Wright; Daniel W Lin; Brandy Klotzle; Marina Bibikova; Jian-Bing Fan; Elaine A Ostrander; Ziding Feng; Janet L Stanford
Journal:  Cancer       Date:  2016-05-03       Impact factor: 6.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.